![]() |
|
|
Vol. 281, Issue 3, 1127-1135, 1997
Departments of
Parasitology (J.G., O.N.),
Pharmaceutical
Chemistry (A.D., D.T.) and
Biological Chemistry (A.T., Z.I.C.), The
Hebrew University, Jerusalem, Israel;
Lady Davis Institute of Research
(P.P.), Jewish General Hospital, McGill University, Montreal, Canada;
Department of Microbiology (W.E.), University of Nijmegen, Nijmegen,
The Netherlands
The hydrophilic desferrioxamine (DFO) and the lipophilic
salicylaldehyde isonicotinoyl hydrazone (SIH) are iron chelators which
inhibit in vitro proliferation of Plasmodium
falciparum with similar potency (IC50 ~20 µM in
24- to 48-h tests). The in vivo assessment of these
drugs was performed on Swiss mice infected with
Plasmodium vinckei petteri with novel
modes of drug administration and release. The drugs were delivered
postpatently either by multiple i.p. injections or by a single i.p. or
s.c. insertion of a drug-containing polymeric device which released
most of the drug within 7 days at apparently first-order rates. A
regimen of three daily i.p injections of 5 mg DFO for 3 consecutive
days or a 70-mg dose of the drug given as an i.p. or s.c. polymer
implant evoked similar delay and reduction in peak parasitemias and
reduced mortality with no apparent signs of toxicity. Relatively
faster, but otherwise similar results were obtained with the less
hydrophilic SIH. In combination, the two drugs apparently potentiated
each other. The polymeric devices were particularly useful for treating
Plasmodium berghei K173-infected C57Bl
mice, a suggested model of cerebral malaria, in which classical methods
of DFO delivery were ineffective. The insertion of a 140-mg
DFO-containing device on day 6 postinfection (parasitemia ~1%) led
to a marked reduction in parasite proliferation, appearance of
neurological sequelae and mortality of mice. Our studies indicate that
polymeric devices for slow drug release might be highly advantageous
for both hydrophilic and lipophilic drugs whose antimalarial efficacy
might depend on the maintenance of sustained blood levels. The results
obtained with slow-release devices have implications for malaria
chemotherapy as well as for iron chelation therapy in iron overload
conditions.
This article has been cited by other articles:
![]() |
M Sterba, T Simunek, Y Mazurova, M Adamcova, O Popelova, J Kaplanova, P Ponka, and V Gersl Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits Human and Experimental Toxicology, November 1, 2005; 24(11): 581 - 589. [Abstract] [PDF] |
||||
![]() |
K. Blaha, M. Cikrt, J. Nerudova, H. Fornuskova, and P. Ponka Biliary Iron Excretion in Rats Following Treatment With Analogs of Pyridoxal Isonicotinoyl Hydrazone Blood, June 1, 1998; 91(11): 4368 - 4372. [Abstract] [Full Text] [PDF] |
||||